TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04199793

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lavare On
Description: For the patients randomized to Lavare On group, the Lavare™ cycle will be turned on upon device interrogation after patients return to intensive care unit from the operating room.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lavare Off
Description: For the patients randomized to Lavare Off group, the Lavare™ cycle will be turned off upon device interrogation after patients return to intensive care unit from the operating room.
Study: NCT03058822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-931699
Description: BMS-931699 single subcutaneous dose on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-931699
Description: BMS-931699 single subcutaneous dose on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-931699
Description: BMS-931699 single subcutaneous dose on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-931699
Description: BMS-931699 single subcutaneous dose on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-931699
Description: BMS-931699 single subcutaneous dose on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-931699
Description: BMS-931699 single subcutaneous dose on Day 1
Study: NCT01078987

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Plasmapheresis
Description: A course of 5 daily treatments of plasma exchange (plasmapheresis) for one to three courses

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Plasmapheresis
Description: A course of 5 daily treatments of plasma exchange (plasmapheresis) for one to three courses

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Plasmapheresis
Description: A course of 5 daily treatments of plasma exchange (plasmapheresis) for one to three courses
Study: NCT02333006

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaires
Description: Traumatic brain injury patients and participant without neurological deficits will answer to questionnaires about Anosognosia
Study: NCT01256203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solar Protection Formula SPF® 60
Description: Solar Protection Formula SPF® 60 (2 mg/cm²) will be topically applied on a randomly predetermined specific skin area on the back of each subject on four separate occasions over 3 months. The same skin area will never be exposed more than once to the sunscreen.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Photobiological testing
Description: Photobiological testing will consist of exposing a small area of the sunscreen-protected and unprotected (control) skin areas to visible light on four separate occasions over 3 months. Light will be applied 30 minutes after application of the sunscreen. The same skin area will never be exposed more than once to light.
Study: NCT04530396

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gam-COVID-Vac
Description: vaccine for intramuscular injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo comparator
Study: NCT01752439

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham transcranial direct current stimulation
Study: NCT03589820

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: artificial liver support system
Description: Patients will receive the treatment of artificial liver support system using combination of plasma exchange and continuous hemodiafiltration and internal medicine. The volume of fresh frozen plasma used in plasma exchange is 2000 millilitre. The time for continuous hemodiafiltration is about 8 hours.
Study: NCT00661102

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroids
Description: As prescribed

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: As prescribed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine [Xeloda]
Description: As prescribed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine [Xeloda]
Description: As prescribed

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: capecitabine [Xeloda]
Description: As prescribed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexpantenol [Bepantol]
Description: As prescribed
Study: NCT04029324

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: tooth extraction
Description: Under local anesthesia, tooth will be extracted atraumatically.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tooth extraction
Description: Under local anesthesia, tooth will be extracted atraumatically.
Study: NCT01365793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.45% saline replacement fluid
Description: 10cc/Kg bolus of 0.9% saline followed by 0.45% saline used as the replacement fluid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.9% saline replacement fluid
Description: 10cc/Kg bolus of 0.9% saline followed by 0.9% saline used as the replacement fluid.
Study: NCT05033574

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound examination
Description: Ultrasound examination of the pelvic organs in girls and the scrotum organs in boys
Study: NCT01365793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.45% saline intravenous fluid
Description: 0.45% saline fluid
Study: NCT05033574

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound examination
Description: Ultrasound examination of the pelvic organs in girls and the scrotum organs in boys

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound examination
Description: Ultrasound examination of the pelvic organs in girls and the scrotum organs in boys

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound examination
Description: Ultrasound examination of the pelvic organs in girls and the scrotum organs in boys

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound examination
Description: Ultrasound examination of the pelvic organs in girls and the scrotum organs in boys

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound examination
Description: Ultrasound examination of the pelvic organs in girls and the scrotum organs in boys

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound examination
Description: Ultrasound examination of the pelvic organs in girls and the scrotum organs in boys

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound examination
Description: Ultrasound examination of the pelvic organs in girls and the scrotum organs in boys
Study: NCT01365793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.9% saline Intravenous fluid
Description: 0.9% saline fluid
Study: NCT03895294

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health care under the strategic purchase-Clinical pathway
Description: 1) purchase of DAA by the MoHSP; 2) diagnosis of the patient (confirmed by quantitative HCV RNA test); 2) prescription of the treatment by a specialist in internal medicine, hepatology or Infectious disease; 3) daily supervised drug administration by a nurse or weekly treatment dispensing by pharmacist; 4) Pharmaceutical Care (includes: consultation with pharmacist at weeks 0, 4, week of the end of treatment (8, 12 or 24) and week of evaluation of effectiveness (week 12 or 24 after the end of treatment); health education and administrative support. In case of identifying any Drug-related Problem, the respective pharmaceutical intervention was made.
Study: NCT04029324

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Implant placement
Description: Dental implants will be placed according to the instructions in fresh sockets or alveolar ridge.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implant placement
Description: Dental implants will be placed according to the instructions in fresh sockets or alveolar ridge.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Bone augmentation
Description: Bone substitute will be used to augment or maintain the bone contour.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone augmentation
Description: Bone substitute will be used to augment or maintain the bone contour.
Study: NCT05033574

Intervention type: RADIATION
Intervention: Radiography of the hands
Description: Determination of bone age using radiography of the hands

Intervention type: RADIATION
Intervention: Radiography of the hands
Description: Determination of bone age using radiography of the hands
Study: NCT04029324

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Coronally repositioned flap
Description: After periosteal releasing incision, mucoperiosteal flap will be sutured at a more coronally position
Study: NCT01962285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol targel controlled infusion
Description: slow stepped propofol target controlled infusion using Schinider´s pharmacokinetic parameters seriated venous blood sampling
Study: NCT00411086

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 By Vein Weekly on Days 1, 8, 15, and 22.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sargramostim (GM-CSF)
Description: 250 mcg subcutaneously three times weekly for 8 weeks, starting at least 1 hour before first dose of rituximab.
Study: NCT05033574

Intervention type: RADIATION
Intervention: Radiography of the hands
Description: Determination of bone age using radiography of the hands

Intervention type: RADIATION
Intervention: Radiography of the hands
Description: Determination of bone age using radiography of the hands

Intervention type: RADIATION
Intervention: Radiography of the hands
Description: Determination of bone age using radiography of the hands

Intervention type: RADIATION
Intervention: Radiography of the hands
Description: Determination of bone age using radiography of the hands

Intervention type: RADIATION
Intervention: Radiography of the hands
Description: Determination of bone age using radiography of the hands

Intervention type: RADIATION
Intervention: Radiography of the hands
Description: Determination of bone age using radiography of the hands

Intervention type: BEHAVIORAL
Intervention: Consultation of a medical psychologist
Description: Consultation with a medical psychologist to determine the patient's psychological condition and level of intelligence

Intervention type: BEHAVIORAL
Intervention: Consultation of a medical psychologist
Description: Consultation with a medical psychologist to determine the patient's psychological condition and level of intelligence

Intervention type: BEHAVIORAL
Intervention: Consultation of a medical psychologist
Description: Consultation with a medical psychologist to determine the patient's psychological condition and level of intelligence
Study: NCT03895294

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care process prior strategic purchase-clinical pathway
Description: 1) diagnosis of the patient (confirmed by quantitative HCV RNA test); 2) prescription of the treatment by a specialist in hepatology; 3) weekly treatment dispensing by pharmacist; 4) patient use; 5) Pharmaceutical Care (includes: consultation with pharmacist at weeks 0, 4, 8, week of the end of treatment (12 or 24) and week of evaluation of effectiveness (week 12 or 24 after the end of treatment); health education and administrative support). In case of identifying any Drug-related problem, the respective pharmaceutical intervention was made.
Study: NCT05033574

Intervention type: BEHAVIORAL
Intervention: Consultation of a medical psychologist
Description: Consultation with a medical psychologist to determine the patient's psychological condition and level of intelligence

Intervention type: BEHAVIORAL
Intervention: Consultation of a medical psychologist
Description: Consultation with a medical psychologist to determine the patient's psychological condition and level of intelligence

Intervention type: BEHAVIORAL
Intervention: Consultation of a medical psychologist
Description: Consultation with a medical psychologist to determine the patient's psychological condition and level of intelligence

Intervention type: BEHAVIORAL
Intervention: Consultation of a medical psychologist
Description: Consultation with a medical psychologist to determine the patient's psychological condition and level of intelligence

Intervention type: BEHAVIORAL
Intervention: Consultation of a medical psychologist
Description: Consultation with a medical psychologist to determine the patient's psychological condition and level of intelligence
Study: NCT03195777

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/CT
Description: PET/CT imaging will be performed (with fluorodeoxyglucose, \[FDG\] as a tracer). Thereafter, subjects will be monitored for development of PTS. We will then assess the ability of PET/CT top predict the subsequent development of PTS.
Study: NCT00973401

Intervention type: OTHER
Intervention: Insulin pump
Description: Patients receive an insulin pump that optimizes their glucose control.
Study: NCT02803229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adderall-XR

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matched placebo
Description: matched placebo provided for placebo arm
Study: NCT01904617

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dextrose

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dextrose

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal Saline

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal Saline

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal Saline
Study: NCT03164785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jinshuibao Capsule
Description: 1.98g t.i.d. p.o. for 6 months
Study: NCT03384524

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bromocriptine 2.5 MG
Description: Administered daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol 25 MG
Description: Administered daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin 0.4 MG
Description: Administered daily
Study: NCT00500747

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HCV E1E2/MF59
Description: The investigational vaccine contains envelope glycoproteins gpE1 and gpE2 and the adjuvant, MF59. MF59 is a sterile oil-in-water emulsion in a citrate buffer, which comprises 50 percent of the vaccine. The antigen and adjuvant are combined prior to the injection. The volume to be administered is 0.5 mL for all vaccine dose levels. The vaccine has a milky white opacity. Vaccine dosages: 4 mcg, 20 mcg and 100 mcg.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HCV E1E2/MF59
Description: The investigational vaccine contains envelope glycoproteins gpE1 and gpE2 and the adjuvant, MF59. MF59 is a sterile oil-in-water emulsion in a citrate buffer, which comprises 50 percent of the vaccine. The antigen and adjuvant are combined prior to the injection. The volume to be administered is 0.5 mL for all vaccine dose levels. The vaccine has a milky white opacity. Vaccine dosages: 4 mcg, 20 mcg and 100 mcg.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HCV E1E2/MF59
Description: The investigational vaccine contains envelope glycoproteins gpE1 and gpE2 and the adjuvant, MF59. MF59 is a sterile oil-in-water emulsion in a citrate buffer, which comprises 50 percent of the vaccine. The antigen and adjuvant are combined prior to the injection. The volume to be administered is 0.5 mL for all vaccine dose levels. The vaccine has a milky white opacity. Vaccine dosages: 4 mcg, 20 mcg and 100 mcg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Four doses sterile saline (0.5 mL total volume) at 0, 4, 24, and 28 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Four doses sterile saline (0.5 mL total volume) at 0, 4, 24, and 28 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Four doses sterile saline (0.5 mL total volume) at 0, 4, 24, and 28 weeks.
Study: NCT03384524

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Three pills, matching active drugs to be administered daily
Study: NCT01113996

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Protein supplementation and strength training
Description: Protein supplementation and strength training

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein supplementation
Description: Protein supplementation
Study: NCT02238548

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Cholera vaccination
Description: Oral cholera vaccination on day 0 and day 14

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cholera vaccination
Description: Oral cholera vaccination on day 0 and day 14

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cholera vaccination
Description: Oral cholera vaccination on day 0 and day 14

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Raw milk

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Raw milk
Study: NCT06397742

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity
Description: Patients received a set of exercises to execute at home. The home exercise program comprised 12 exercises conducted in sequence:~1. Symmetrical shoulder raises with retraction~2. Rolling upper extremities using a ball~3. Symmetrical shoulder raises~4. Band exercises strengthening the upper girdle and arm~5. Exercise of the shoulder joint flexors~6. Side arm raises in supine position~7. Lateral arm raises in supine position~8. Head raises with rotation in supine position~9. Side arm raises in prone position~10. Front arm raises in prone position~11. Rising and lowering the upper girdle in prone position~12. Neck muscles stretches

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy - myofascial techniques
Description: Physical therapy program comprised five parts. I. Fascial manipulation targeted three most active center of coordination - center of fusion points within head, neck, shoulder, shoulder blade, or chest - during each session, time depending on the patients' adaptability.~II. Manual mobilization of the scar area with each training session including: active myofascial stretching; manual scar mobilization by stretching perpendicularly and in parallel with the scar; soft tissue mobilization by rolling and pulling the surface tissues; myofascial relaxation by breaking through restrictions.~III. Relaxation of muscle contractures using post-isometric muscle relaxation of the scalene muscle, sternocleidomastoid muscle, and neck muscles - until the sessions provided no muscle elongation.~IV. Neuromuscular stimulation with proprioceptive neuromuscular facilitation - included scapula movement patterns, dynamic reversal, stabilizing reversal, upper extremity movement patterns.
Study: NCT00830960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: Oral, daily, 90 days
Study: NCT03318276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SID142
Description: SID142 is administrated to patients with PAD for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rinexin® Tab
Description: Rinexin® Tab is administrated to patients with PAD for 12 weeks
Study: NCT04435821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]FTC-146
Description: Participants will be injected with 0.08 mCi/kg \[18F\]FTC-146. A whole-body PET/MRI scan will be performed after injection.
Study: NCT01829841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famitinib
Description: Famitinib 25 mg p.o. qd

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib
Description: Sunitinib 50 mg p.o. qd
Study: NCT00522171

Intervention type: DEVICE
Intervention: The Harmonic™ ultrasonic scalpel
Description: A surgical instrument that uses ultrasonic energy that allows both cutting and coagulating at the precise point of application.
Study: NCT02262793

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: telmisartan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telmisartan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telmisartan
Study: NCT01798381

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Essential fatty acids

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Essential fatty acids
Study: NCT01971684

Intervention type: DRUG
Intervention: Second Line ITP agents
Description: The treating physicians will select the second line agent and clinical data will be collected.
Study: NCT00830960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: Oral, daily, 90 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: Oral, daily, 90 days
Study: NCT01789242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: IV over 30 minutes on Days 1, 2, 8, 9, 15, and 16 every 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone IV or PO on Days 1, 2, 8, 9, 15, and 16 every 28 days in patients with \<VGPR after 4 cycles.
Study: NCT04624516

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: self-structured foot exercise
Description: The exercise was done 3 times a week (15x/until they tired x 2set). The exercise used a flexible band with difference thickness (0,5 mm in the first 12 weeks and 0,65 mm in the second 12 weeks)
Study: NCT01730911

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Text message
Description: Participants will receive daily text messages to report bleeding and cramping experienced, if they are randomized to this arm.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Text message
Description: Participants will receive daily text messages to report bleeding and cramping experienced, if they are randomized to this arm.
Study: NCT03759236

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Messaging via SMS
Description: This intervention aims to provide health education on topics including HPV Vaccination, Cervical Cancer screening, contraceptive methods, menstrual problems, diet and exercise geared towards women with children of vaccination age.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CDC Health Pamphlets
Description: This intervention aims to provide health education on the HPV Vaccination to women with children of vaccination age.
Study: NCT00830960

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Oral, daily, 90 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Oral, daily, 90 days
Study: NCT01223326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcysteine (NAC)
Description: NAC 150 mg/Kg; and infusion of 50 mg/kg, from 30 minutes before the ischemia up to 60 minutes later to the reperfusion